Clinical Trials

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05030506 2025-12-18

MK-6482-010

45 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05899049 2025-11-10

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

249 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05239728 2025-08-14

MK-6482-022

1,800 enrolled

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04626518 2025-07-25

KEYMAKER-U03

370 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02974738 2025-07-10

MK-6482-001

120 enrolled

CNSGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Kidney Neoplasms, Neoplasm Metastasis

NCT04195750 2025-04-29

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

755 enrolled 28 charts 1 FDA

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04489771 2025-02-11

MK-6482-013

154 enrolled 19 charts

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03634540 2024-12-20

MK-6482-003

118 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT04846920 2024-11-22

MK-6482-018

52 enrolled

Carcinoma, Renal Cell

NCT04736706 2024-11-18

MK-6482-012

1,653 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02293980 2024-06-17

MK-3795-001

110 enrolled